10558-45-9Relevant articles and documents
Niclosamide quantification in methyl-β-cyclodextrin after derivatization to aminoniclosamide
Algarra, Manuel,Campos, Bruno B.,Rodriguez-Borges, Jose E.,Sanchez, Francisco G.,Lopez-Romero, Juan M.,Esteves Da Silva, Joaquim C. G.
, p. 89 - 94 (2012)
A fluorescence derivatization method for the quantification of the anthelmintic drug niclosamide in organized media (methyl-β-cyclodextrin) is described. The derivatization reaction is based on a 3 h reduction reaction of the nitro group in niclosamide to an amino group by hydrogenation catalyzed by Pd/C in methanol:ethyl acetate (1:3). The aminoniclosamide exhibits a maximum of fluorescence at 431 nm (excitation at 280 nm) that is markedly enhanced when methyl-β-cyclodextrin is present. The methodology was assessed by the analysis of pure and dosage forms. The method showed a linear range between 0 and 2200 μg L-1 with a limit of detection of 45.7 nL and a precision (relative standard deviation) of 4.1% in niclosamide. The effect of various interferents, such as niclosamide, fructose and 2-cyano-6- metoxybenzothiazole, in several tolerance ratios, was investigated respected to aminoniclosamide.
SALICYLAMIDE DERIVATIVES AND RELATED METHODS OF MAKING
-
Paragraph 0209; 0210, (2021/07/31)
Certain embodiments describe antiviral compounds and related methods of using such compounds.
Substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues potently inhibit respiratory syncytial virus (RSV) replication and RSV infection-associated inflammatory responses
Xu, Jimin,Wu, Wenzhe,Chen, Haiying,Xue, Yu,Bao, Xiaoyong,Zhou, Jia
, (2021/04/29)
Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection in young children, and specific treatment for RSV infections remains unavailable. We herein reported a series of substituted N-(4-amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent RSV inhibitors. Among them, six low cytotoxic compounds (11, 12, 15, 22, 26, and 28) have been identified and selected to study associated inhibitory mechanisms. All these compounds suppressed not only the viral replication but also RSV-induced IRF3 and NF-κB activation and associated production of cytokines/chemokines. The two most potent compounds (15 and 22) were selected for further molecular mechanism studies associated with their suppression effect on RSV-activated IRF3 and NF-κB. These two compounds decreased RSV-induced IRF3 phosphorylation at serine 396 and p65 phosphorylation at serine 536 at both early and late infection phases. In addition, compound 22 also inhibited RSV-induced p65 phosphorylation at serine 276 at the late phase of RSV infection.
Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors
Xu, Jimin,Berastegui-Cabrera, Judith,Ye, Na,Carretero-Ledesma, Marta,Pachón-Díaz, Jerónimo,Chen, Haiying,Pachón-Ibá?ez, Maria Eugenia,Sánchez-Céspedes, Javier,Zhou, Jia
, p. 12830 - 12852 (2020/11/13)
An effective therapy for human adenovirus (HAdV) infections in immunocompromised patients and healthy individuals with community-Acquired pneumonia remains an unmet medical need. We herein reported a series of novel substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent HAdV inhibitors. Compounds 6, 15, 29, 40, 43, 46, 47, and 54 exhibited increased selectivity indexes (SI > 100) compared to the lead compound niclosamide, while maintaining sub-micromolar to low micromolar potency against HAdV. The preliminary mechanistic studies indicated that compounds 6 and 43 possibly target the HAdV DNA replication process, while compounds 46 and 47 suppress later steps of HAdV life cycle. Notably, among these derivatives, compound 15 showed improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreased cytotoxicity (CC50 = 156.8 μM), and low in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further in vivo efficacy studies for the treatment of HAdV infections.
